Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.52 |
| ▸ | PPARG | P37231 | 11/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FABP2 | P12104 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840876 | 0.82 | ADRB3 (0.67) | PPARAPPARGPPARDADRB3ALDH1A1 | |
| SCHEMBL12328025 | 0.82 | ADRB3 (0.67) | PPARAPPARGPPARDADRB3ALDH1A1 | |
| SCHEMBL2440421 | 0.78 | PPARA (0.66) | PPARAPPARGPPARDADRB3ALDH1A1 | |
| SCHEMBL3848024 | 0.77 | ADRB3 (0.73) | PPARAPPARGPPARDADRB3ALDH1A1 | |
| SCHEMBL12953439 | 0.76 | PPARG (0.74) | PPARAPPARGPPARDADRB3 | |
| SCHEMBL3841460 | 0.74 | PPARA (0.59) | PPARAPPARGPPARDADRB3ALDH1A1 | |
| SCHEMBL4576026 | 0.73 | PPARA (0.54) | PPARAPPARGADRB3 | |
| SCHEMBL29079326 | 0.72 | PPARA (0.60) | PPARAPPARGPPARDADRB3ALDH1A1 | |
| SCHEMBL4575444 | 0.71 | PPARA (0.75) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL12953097 | 0.71 | PPARG (0.71) | PPARAPPARGPPARDADRB3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132145-B2 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | NEW YORK UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | LPL, ADIPOR2, EBP | PPARA 24/4885PPARG 42/4885PPARD 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.